vimarsana.com

Latest Breaking News On - Johnson medtech companies - Page 1 : vimarsana.com

Late Breaking Data on Pulmonary Vein Isolation with HELIOSTAR™ Balloon Ablation Catheter Presented at AF Symposium 2023

Late Breaking Data on Pulmonary Vein Isolation with HELIOSTAR™ Balloon Ablation Catheter Presented at AF Symposium 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

First Look at Data on Biosense Webster s Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023

Late Breaking Data on Pulmonary Vein Isolation with HELIOSTAR™ Balloon Ablation Catheter Presented at AF Symposium 2023

Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation

A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ Biosense Webster, Inc., part of Johnson & Johnson MedTech[], today announced the release of a report titled, 'Atrial Fibrillation Exacts Toll on Women: Addressing the Gender Disparity in the Treatment and Management of Atrial Fibrillation in the Asia-Pacific Region'. Endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the report brings together a panel of experts from various geographic locations including Australia, China, Japan, and Singapore, among others to address the unique features of Atrial Fibrillation (AFib) in women and provide recommendations for improving its management across the region. AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide.[1] It is a progressive disease, and if left untreated, can g

Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation

A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ Biosense Webster, Inc., part of Johnson & Johnson MedTech[], today announced the release of a report titled, 'Atrial Fibrillation Exacts Toll on Women: Addressing the Gender Disparity in the Treatment and Management of Atrial Fibrillation in the Asia-Pacific Region'. Endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the report brings together a panel of experts from various geographic locations including Australia, China, Japan, and Singapore, among others to address the unique features of Atrial Fibrillation (AFib) in women and provide recommendations for improving its management across the region. AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide.[1] It is a progressive disease, and if left untreated, can g

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.